Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy

Pan,Xiu-Wu; Li,Lin; Huang,Yi; Huang,Hai; Xu,Dan-Feng; Gao,Yi; Chen,Lu; Ren,Ji-Zhong; Cao,Jian-Wei; Hong,Yi; Cui,Xin-Gang

doi:10.3892/or.2015.4335

Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy

Authors:
- Xiu-Wu Pan
- Lin Li
- Yi Huang
- Hai Huang
- Dan-Feng Xu
- Yi Gao
- Lu Chen
- Ji-Zhong Ren
- Jian-Wei Cao
- Yi Hong
- Xin-Gang Cui
View Affiliations

Affiliations: Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Sanghai 200003, P.R. China, The Urology Research Center of the Chinese People's Liberation Army, Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China, Navy No. 411 Hospital of PLA, Hongkou, Shanghai 200003, P.R. China
Published online on: October 16, 2015 https://doi.org/10.3892/or.2015.4335
Pages: 334-342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is one of the most commonly diagnosed urological malignancies. Acquired resistance to chemotherapy is a great barrier for achieving successful treatment of bladder cancer. In the present study, we investigated the effect and mechanisms of icaritin, a flavonol glycoside derived from genus Epimedium, against human bladder cancer cells. It was found that despite the low cytotoxicity in normal human HEK293 cells, icaritin significantly inhibited the proliferation and colony formation of BT5637 and T24 bladder cancer cells time- and dose-dependently compared to the DMSO vehicle control. Moreover, cell viability monitored through mitochondrial membrane potential was inhibited markedly after icaritin treatment. Further investigation indicated that icaritin may inhibit epirubicin (EPI)-induced autophagy, and acted synergistically with EPI to suppress the proliferation of BT5637 and T24 cells. These findings suggest that icaritin may prove to be a novel potent therapeutic agent for the treatment of bladder cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Parekh DJ, Bochner BH and Dalbagni G: Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments. J Clin Oncol. 24:5519–5527. 2006. View Article : Google Scholar : PubMed/NCBI
4	Herr HW: Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 15:84–88. 1997. View Article : Google Scholar : PubMed/NCBI
5	Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W and Giani G: Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 139:283–285. 1988.PubMed/NCBI
6	Onrust SV, Wiseman LR and Goa KL: Epirubicin: A review of its intravesical use in superficial bladder cancer. Drugs Aging. 15:307–333. 1999. View Article : Google Scholar : PubMed/NCBI
7	Wu H, Lien EJ and Lien LL: Chemical and pharmacological investigations of Epimedium species: A survey. Prog Drug Res. 60:1–57. 2003. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Zhang X, Wang H, Qi L and Lou Y: Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuroscience. 145:911–922. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Wang H, Wu J, Zhu D, Zhang X, Ou L, Yu Y and Lou Y: Enhanced co-expression of beta-tubulin III and choline acetyltransferase in neurons from mouse embryonic stem cells promoted by icaritin in an estrogen receptor-independent manner. Chem Biol Interact. 179:375–385. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wo YB, Zhu DY, Hu Y, Wang ZQ, Liu J and Lou YJ: Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J Cell Biochem. 103:1536–1550. 2008. View Article : Google Scholar
11	Zhu DY and Lou YJ: Inducible effects of icariin, icaritin, and desmethylicaritin on directional differentiation of embryonic stem cells into cardiomyocytes in vitro. Acta Pharmacol Sin. 26:477–485. 2005. View Article : Google Scholar : PubMed/NCBI
12	Huang J, Yuan L, Wang X, Zhang TL and Wang K: Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci. 81:832–840. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen MF, Qi L, Li Y, Zu XB, Dai YQ and Zhang P: Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner. Amino Acids. 38:1505–1513. 2010. View Article : Google Scholar
14	Hong J, Zhang Z, Lv W, Zhang M, Chen C, Yang S, Li S, Zhang L, Han D and Zhang W: Icaritin synergistically enhances the radio-sensitivity of 4T1 breast cancer cells. PLoS One. 8:e713472013. View Article : Google Scholar
15	Tong JS, Zhang QH, Huang X, Fu XQ, Qi ST, Wang YP, Hou Y, Sheng J and Sun QY: Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One. 6:e167812011. View Article : Google Scholar : PubMed/NCBI
16	Huang X, Zhu D and Lou Y: A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol. 564:26–36. 2007. View Article : Google Scholar : PubMed/NCBI
17	Guo Y, Zhang X, Meng J and Wang ZY: An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 658:114–122. 2011. View Article : Google Scholar : PubMed/NCBI
18	Li S, Priceman SJ, Xin H, Zhang W, Deng J, Liu Y, Huang J, Zhu W, Chen M, Hu W, et al: Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 8:e816572013. View Article : Google Scholar : PubMed/NCBI
19	Yang ZJ, Chee CE, Huang S and Sinicrope FA: The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
20	Sun WL, Chen J, Wang YP and Zheng H: Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy. 7:1035–1044. 2011. View Article : Google Scholar : PubMed/NCBI
21	Xie JM, Li B, Yu HP, Gao QG, Li W, Wu HR and Qin ZH: TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy. Cancer Res. 74:5127–5138. 2014. View Article : Google Scholar : PubMed/NCBI
22	Chen WC, Hsu KY, Hung CM, Lin YC, Yang NS, Ho CT, Kuo SC and Way TD: The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells. Food Funct. 5:1856–1865. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tang Q, Li G, Wei X, Zhang J, Chiu JF, Hasenmayer D, Zhang D and Zhang H: Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Lett. 336:325–337. 2013. View Article : Google Scholar : PubMed/NCBI
24	Cui Q, Tashiro S, Onodera S, Minami M and Ikejima T: Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 30:859–864. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zhang XQ, Dunner K Jr and Benedict WF: Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced. Cancer Gene Ther. 17:579–584. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sang H, Zhang L and Li J: Anti-benzopyrene-7,8-diol-9,10-epoxide induces apoptosis via mitochondrial pathway in human bronchiolar epithelium cells independent of the mitochondria permeability transition pore. Food Chem Toxicol. 50:2417–2423. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
28	McBride HM, Neuspiel M and Wasiak S: Mitochondria: More than just a powerhouse. Curr Biol. 16:R551–R560. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yang CC, Chen GW, Lu HF, Wang DY, Chen YS and Chung JG: Paclitaxel (taxol) inhibits the arylamine N-acetyltransferase activity and gene expression (mRNA NAT1) and 2-aminofluo-rene-DNA adduct formation in human bladder carcinoma cells (T24 and TSGH 8301). Pharmacol Toxicol. 92:287–294. 2003. View Article : Google Scholar : PubMed/NCBI
30	Li S, Dong P, Wang J, Zhang J, Gu J, Wu X, Wu W, Fei X, Zhang Z, Wang Y, et al: Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Lett. 298:222–230. 2010. View Article : Google Scholar : PubMed/NCBI
31	Weinberg F and Chandel NS: Mitochondrial metabolism and cancer. Ann NY Acad Sci. 1177:66–73. 2009. View Article : Google Scholar : PubMed/NCBI
32	Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007. View Article : Google Scholar : PubMed/NCBI
33	Tanida I, Ueno T and Kominami E: LC3 and Autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
34	Yamaguchi M, Noda NN, Yamamoto H, Shima T, Kumeta H, Kobashigawa Y, Akada R, Ohsumi Y and Inagaki F: Structural insights into Atg10-mediated formation of the autophagy-essential Atg12-Atg5 conjugate. Structure. 20:1244–1254. 2012. View Article : Google Scholar : PubMed/NCBI
35	Zhu J, Li Z, Zhang G, Meng K, Kuang W, Li J, Zhou X, Li R, Peng H, Dai C, et al: Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS One. 6:e237202011. View Article : Google Scholar
36	Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, et al: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 20:3159–3173. 2014. View Article : Google Scholar : PubMed/NCBI